denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.Hematology Disease Topics & Pathways:
Hodgkin lymphoma, Biological therapies, Clinical Practice (Health Services and Quality), Lymphomas, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Diseases, Therapies, Lymphoid Malignancies, Technology and Procedures
Description:
The addition of novel therapeutic agents has changed the standard of care for advanced-stage and relapsed/refractory classic Hodgkin lymphoma (cHL). Limited-stage disease has traditionally been treated with combination chemotherapy with or without consolidative radiation. Novel therapeutics are actively being integrated into frontline therapy for limited-stage disease to improve acute survival rates and optimize longer-term outcomes. Historically, survival rates have been modest for older cHL patients. However, a renewed effort globally has resulted in the generation of a multitude of new real-world and clinical trial data. In addition, there remains an unmet need to identify therapeutic options for cHL patients who have progressed after brentuximab vedotin and PD-1 blockade.
Dr. Sairah Ahmed will discuss the treatment of limited-stage cHL with standard frontline chemotherapy or combined modality therapy. As CD30-directed antibody-drug conjugate brentuximab vedotin and PD-1 blockade have transformed the treatment of relapsed/refractory cHL, recent studies incorporating these agents in limited-stage disease will be explored.
Dr. Andy Evens will examine current real-world and clinical trial data for older cHL patients, emphasizing prognostication, geriatric assessments, treatment intensity, anthracycline use, integration of targeted therapeutic agents, and post-acute survivorship. Patient management and evidence-based data for therapeutic decision-making will be evaluated.
Dr. Natalie Grover will discuss the treatment of relapsed/refractory cHL in patients whose disease has progressed after brentuximab vedotin and PD-1 blockade. Using a case-based approach, therapeutic options for these challenging cases will be presented, including the role of cytotoxic chemotherapy, allogeneic stem cell transplantation, and clinical trial results with novel agents, including chimeric antigen receptor T-cells.
Dr. Sairah Ahmed will discuss the treatment of limited-stage cHL with standard frontline chemotherapy or combined modality therapy. As CD30-directed antibody-drug conjugate brentuximab vedotin and PD-1 blockade have transformed the treatment of relapsed/refractory cHL, recent studies incorporating these agents in limited-stage disease will be explored.
Dr. Andy Evens will examine current real-world and clinical trial data for older cHL patients, emphasizing prognostication, geriatric assessments, treatment intensity, anthracycline use, integration of targeted therapeutic agents, and post-acute survivorship. Patient management and evidence-based data for therapeutic decision-making will be evaluated.
Dr. Natalie Grover will discuss the treatment of relapsed/refractory cHL in patients whose disease has progressed after brentuximab vedotin and PD-1 blockade. Using a case-based approach, therapeutic options for these challenging cases will be presented, including the role of cytotoxic chemotherapy, allogeneic stem cell transplantation, and clinical trial results with novel agents, including chimeric antigen receptor T-cells.